When the global pharma community gets wind of the face that this small company is doing a trial with a safe repurposed drug, in a country where the drug is already legal, on a type of illness in which it's already got demonstrated effect, tested with physicians who have agreed to use it, among a period of high global need, you will see volume spike immensely.
The sheer magnitude of this news is clearly not understood by the average investors, as demonstrated by the volume and share price.
News 
Market Data 
Discover 
AI
